GenEdit, Inc., a Berkeley, CA-based developer of novel polymer nanoparticle technology platform for non-viral-based delivery of gene therapeutics, completed an $8.5m seed financing.
The round was led by new investors Data Collective Bio and SK Holdings, with participation from pre-seed investors Sequoia Capital and Bow Capital. In conjunction with the funding, DCVC Bio Managing Partner, Kiersten Stead, Ph.D., and Natera co-founder and CEO, Matthew Rabinowitz, Ph.D., joined GenEdit’s Board of Directors.
The company intends to use the funds to continue to build and advance its proprietary polymer nanoparticle system.
Launched in 2016 by UC Berkeley scientists, Kunwoo Lee, Hyo Min Park, and Niren Murthy, who is Professor of Bioengineering, GenEdit has developed its proprietary polymer nanoparticle library, establishing initial proof of concept by delivering CRISPR-Cas9 and gene editors to target tissues. The company’s proprietary nanoparticles have broad applicability including the development of CRISPR-based therapeutics and gene therapy products for a wide range of genetic diseases.